These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 22638860)

  • 1. Neuroprotection by silencing iNOS expression in a 6-OHDA model of Parkinson's disease.
    Li M; Dai FR; Du XP; Yang QD; Chen Y
    J Mol Neurosci; 2012 Sep; 48(1):225-33. PubMed ID: 22638860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroprotective effect of omega-3 polyunsaturated fatty acids in the 6-OHDA model of Parkinson's disease is mediated by a reduction of inducible nitric oxide synthase.
    Mori MA; Delattre AM; Carabelli B; Pudell C; Bortolanza M; Staziaki PV; Visentainer JV; Montanher PF; Del Bel EA; Ferraz AC
    Nutr Neurosci; 2018 Jun; 21(5):341-351. PubMed ID: 28221817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pirouetting pigs: A large non-primate animal model based on unilateral 6-hydroxydopamine lesioning of the nigrostriatal pathway.
    Christensen AB; Sørensen JCH; Ettrup KS; Orlowski D; Bjarkam CR
    Brain Res Bull; 2018 May; 139():167-173. PubMed ID: 29462643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD200-CD200R dysfunction exacerbates microglial activation and dopaminergic neurodegeneration in a rat model of Parkinson's disease.
    Zhang S; Wang XJ; Tian LP; Pan J; Lu GQ; Zhang YJ; Ding JQ; Chen SD
    J Neuroinflammation; 2011 Nov; 8():154. PubMed ID: 22053982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective and therapeutic activity of honokiol in reversing motor deficits and neuronal degeneration in the mouse model of Parkinson's disease.
    Chen HH; Chang PC; Chen C; Chan MH
    Pharmacol Rep; 2018 Aug; 70(4):668-676. PubMed ID: 29909247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CX3CR1 Disruption Differentially Influences Dopaminergic Neuron Degeneration in Parkinsonian Mice Depending on the Neurotoxin and Route of Administration.
    Tristão FS; Lazzarini M; Martin S; Amar M; Stühmer W; Kirchhoff F; Gomes LA; Lanfumey L; Prediger RD; Sepulveda JE; Del-Bel EA; Raisman-Vozari R
    Neurotox Res; 2016 Apr; 29(3):364-80. PubMed ID: 26403659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel GLP-1/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson's disease.
    Jalewa J; Sharma MK; Gengler S; Hölscher C
    Neuropharmacology; 2017 May; 117():238-248. PubMed ID: 28223210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A bibenzyl compound 20C protects rats against 6-OHDA-induced damage by regulating adaptive immunity associated molecules.
    Wang S; Han QW; Zhou TT; Zhang CL; Zhu CG; Zhou X; Chen NH; Yuan YH; Shi JG
    Int Immunopharmacol; 2021 Feb; 91():107269. PubMed ID: 33340781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Kv7/KCNQ channel blocker XE991 protects nigral dopaminergic neurons in the 6-hydroxydopamine rat model of Parkinson's disease.
    Liu H; Jia L; Chen X; Shi L; Xie J
    Brain Res Bull; 2018 Mar; 137():132-139. PubMed ID: 29174294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vitamin D protects dopaminergic neurons against neuroinflammation and oxidative stress in hemiparkinsonian rats.
    Lima LAR; Lopes MJP; Costa RO; Lima FAV; Neves KRT; Calou IBF; Andrade GM; Viana GSB
    J Neuroinflammation; 2018 Aug; 15(1):249. PubMed ID: 30170624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson's disease.
    Mulas G; Espa E; Fenu S; Spiga S; Cossu G; Pillai E; Carboni E; Simbula G; Jadžić D; Angius F; Spolitu S; Batetta B; Lecca D; Giuffrida A; Carta AR
    Exp Neurol; 2016 Dec; 286():83-92. PubMed ID: 27697481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tetramethylpyrazine Analogue CXC195 Protects Against Dopaminergic Neuronal Apoptosis via Activation of PI3K/Akt/GSK3β Signaling Pathway in 6-OHDA-Induced Parkinson's Disease Mice.
    Chen L; Cheng L; Wei X; Yuan Z; Wu Y; Wang S; Ren Z; Liu X; Liu H
    Neurochem Res; 2017 Apr; 42(4):1141-1150. PubMed ID: 28005221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of astroglial fibroblast growth factor-2 and microglia in the nigral 6-OHDA parkinsonism and a possible role of glucocorticoid hormone on the glial mediated local trophism and wound repair.
    Silva C; Fuxe K; Chadi G
    J Neural Transm Suppl; 2009; (73):185-202. PubMed ID: 20411778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Protective effect of alkaloids from Piper longum in rat dopaminergic neuron injury of 6-OHDA-induced Parkinson's disease].
    Zheng L; Wang H; Ba YY; Liu HL; Wang M; Guo WW; Wu X; Yang H
    Zhongguo Zhong Yao Za Zhi; 2014 May; 39(9):1660-5. PubMed ID: 25095380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
    Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N
    Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. L-type Cav1.2 calcium channel is involved in 6-hydroxydopamine-induced neurotoxicity in rats.
    Wang R; Ma Z; Wang J; Xie J
    Neurotox Res; 2012 Apr; 21(3):266-70. PubMed ID: 21901331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function.
    Winkler C; Kirik D; Björklund A; Cenci MA
    Neurobiol Dis; 2002 Jul; 10(2):165-86. PubMed ID: 12127155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The 6-hydroxydopamine-induced nigrostriatal neurodegeneration produces microglia-like NG2 glial cells in the rat substantia nigra.
    Kitamura Y; Inden M; Minamino H; Abe M; Takata K; Taniguchi T
    Glia; 2010 Nov; 58(14):1686-700. PubMed ID: 20629191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moutan Cortex Radicis inhibits the nigrostriatal damage in a 6-OHDA-induced Parkinson's disease model.
    Choi YG; Hong YM; Kim LH; Yeo S; Lim S
    Chin J Nat Med; 2018 Jul; 16(7):490-498. PubMed ID: 30080647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranigral transplantation of solid tissue ventral mesencephalon or striatal grafts induces behavioral recovery in 6-OHDA-lesioned rats.
    Palmer MR; Granholm AC; van Horne CG; Giardina KE; Freund RK; Moorhead JW; Gerhardt GA
    Brain Res; 2001 Jan; 890(1):86-99. PubMed ID: 11164771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.